Trials / Completed
CompletedNCT04412668
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- aTyr Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efzofitimod 1 mg/kg | Concentrate for solution for infusion |
| DRUG | Efzofitimod 3 mg/kg | Concentrate for solution for infusion |
| DRUG | Placebo | Concentrate for solution for infusion |
Timeline
- Start date
- 2020-06-04
- Primary completion
- 2020-10-23
- Completion
- 2020-10-23
- First posted
- 2020-06-02
- Last updated
- 2023-08-18
- Results posted
- 2023-08-18
Locations
10 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04412668. Inclusion in this directory is not an endorsement.